FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3128952964> ?p ?o ?g. }

• W3128952964 endingPage "488" @default.
• W3128952964 startingPage "482" @default.
• W3128952964 abstract "Medulloblastoma, the most common pediatric brain malignancy, has Sonic Hedgehog (SHH) and group 3 (Myc driven) subtypes that are associated with the activity of eukaryotic initiation factor 4E (eIF4E), a critical mediator of translation, and enhancer of zeste homolog 2 (EZH2), a histone methyltransferase and master regulator of transcription. Recent drug repurposing efforts in multiple solid and hematologic malignancies have demonstrated that eIF4E and EZH2 are both pharmacologically inhibited by the FDA-approved antiviral drug ribavirin. Given the molecular overlap between medulloblastoma biology and known ribavirin activity, the authors investigated the preclinical efficacy of repurposing ribavirin as a targeted therapeutic in cell and animal models of medulloblastoma.Multiple in vitro assays were performed using human ONS-76 (a primitive SHH model) and D425 (an aggressive group 3 model) cells. The impacts of ribavirin on cellular growth, death, migration, and invasion were quantified using proliferation and Cell Counting Kit-8 (CCK-8) assays, flow cytometry with annexin V (AnnV) staining, scratch wound assays, and Matrigel invasion chambers, respectively. Survival following daily ribavirin treatment (100 mg/kg) was assessed in vivo in immunodeficient mice intracranially implanted with D425 cells.Compared to controls, ribavirin treatment led to a significant reduction in medulloblastoma cell growth (ONS-76 proliferation assay, p = 0.0001; D425 CCK-8 assay, p < 0.0001) and a significant increase in cell death (flow cytometry for AnnV, ONS-76, p = 0.0010; D425, p = 0.0284). In ONS-76 cells, compared to controls, ribavirin significantly decreased cell migration and invasion (Matrigel invasion chamber assay, p = 0.0012). In vivo, ribavirin significantly extended survival in an aggressive group 3 medulloblastoma mouse model compared to vehicle-treated controls (p = 0.0004).The authors demonstrate that ribavirin, a clinically used drug known to inhibit eIF4E and EZH2, has significant antitumor effects in multiple preclinical models of medulloblastoma, including an aggressive group 3 animal model. Ribavirin may represent a promising targeted therapeutic in medulloblastoma." @default.
• W3128952964 created "2021-02-15" @default.
• W3128952964 creator A5010219978 @default.
• W3128952964 creator A5015181749 @default.
• W3128952964 creator A5019417985 @default.
• W3128952964 creator A5027322124 @default.
• W3128952964 creator A5039709663 @default.
• W3128952964 creator A5039917556 @default.
• W3128952964 creator A5045785216 @default.
• W3128952964 creator A5049334243 @default.
• W3128952964 creator A5050597052 @default.
• W3128952964 creator A5055192528 @default.
• W3128952964 creator A5059713182 @default.
• W3128952964 creator A5060287350 @default.
• W3128952964 creator A5064814225 @default.
• W3128952964 creator A5071938042 @default.
• W3128952964 creator A5086406025 @default.
• W3128952964 date "2021-04-01" @default.
• W3128952964 modified "2023-10-09" @default.
• W3128952964 title "Preclinical efficacy of ribavirin in SHH and group 3 medulloblastoma" @default.
• W3128952964 cites W1972388618 @default.
• W3128952964 cites W1980763900 @default.
• W3128952964 cites W1999278711 @default.
• W3128952964 cites W2003307182 @default.
• W3128952964 cites W2011752552 @default.
• W3128952964 cites W2031628375 @default.
• W3128952964 cites W2033120379 @default.
• W3128952964 cites W2051255662 @default.
• W3128952964 cites W2052001124 @default.
• W3128952964 cites W2088174971 @default.
• W3128952964 cites W2088839511 @default.
• W3128952964 cites W2095253522 @default.
• W3128952964 cites W2111967140 @default.
• W3128952964 cites W2112519486 @default.
• W3128952964 cites W2113933978 @default.
• W3128952964 cites W2121836743 @default.
• W3128952964 cites W2142505369 @default.
• W3128952964 cites W2149546612 @default.
• W3128952964 cites W2150794759 @default.
• W3128952964 cites W2151299944 @default.
• W3128952964 cites W2153398041 @default.
• W3128952964 cites W2168957937 @default.
• W3128952964 cites W2169508419 @default.
• W3128952964 cites W2174804804 @default.
• W3128952964 cites W2176184837 @default.
• W3128952964 cites W2264682687 @default.
• W3128952964 cites W2269266363 @default.
• W3128952964 cites W2530065228 @default.
• W3128952964 cites W2562383504 @default.
• W3128952964 cites W2597588248 @default.
• W3128952964 cites W2600491816 @default.
• W3128952964 cites W2737542366 @default.
• W3128952964 cites W2739542332 @default.
• W3128952964 cites W2741344135 @default.
• W3128952964 cites W2780330613 @default.
• W3128952964 cites W2781832221 @default.
• W3128952964 cites W2788681334 @default.
• W3128952964 cites W2893677139 @default.
• W3128952964 cites W2898511841 @default.
• W3128952964 cites W2914744786 @default.
• W3128952964 cites W2953842076 @default.
• W3128952964 cites W3039457499 @default.
• W3128952964 cites W4205285591 @default.
• W3128952964 cites W4211218067 @default.
• W3128952964 doi "https://doi.org/10.3171/2020.8.peds20561" @default.
• W3128952964 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33545678" @default.
• W3128952964 hasPublicationYear "2021" @default.
• W3128952964 type Work @default.
• W3128952964 sameAs 3128952964 @default.
• W3128952964 citedByCount "4" @default.
• W3128952964 countsByYear W31289529642021 @default.
• W3128952964 countsByYear W31289529642022 @default.
• W3128952964 countsByYear W31289529642023 @default.
• W3128952964 crossrefType "journal-article" @default.
• W3128952964 hasAuthorship W3128952964A5010219978 @default.
• W3128952964 hasAuthorship W3128952964A5015181749 @default.
• W3128952964 hasAuthorship W3128952964A5019417985 @default.
• W3128952964 hasAuthorship W3128952964A5027322124 @default.
• W3128952964 hasAuthorship W3128952964A5039709663 @default.
• W3128952964 hasAuthorship W3128952964A5039917556 @default.
• W3128952964 hasAuthorship W3128952964A5045785216 @default.
• W3128952964 hasAuthorship W3128952964A5049334243 @default.
• W3128952964 hasAuthorship W3128952964A5050597052 @default.
• W3128952964 hasAuthorship W3128952964A5055192528 @default.
• W3128952964 hasAuthorship W3128952964A5059713182 @default.
• W3128952964 hasAuthorship W3128952964A5060287350 @default.
• W3128952964 hasAuthorship W3128952964A5064814225 @default.
• W3128952964 hasAuthorship W3128952964A5071938042 @default.
• W3128952964 hasAuthorship W3128952964A5086406025 @default.
• W3128952964 hasBestOaLocation W31289529641 @default.
• W3128952964 hasConcept C2780789225 @default.
• W3128952964 hasConcept C502942594 @default.
• W3128952964 hasConcept C71924100 @default.
• W3128952964 hasConceptScore W3128952964C2780789225 @default.
• W3128952964 hasConceptScore W3128952964C502942594 @default.
• W3128952964 hasConceptScore W3128952964C71924100 @default.
• W3128952964 hasIssue "4" @default.
• W3128952964 hasLocation W31289529641 @default.

• next